Edition:
India

Pfizer Inc Says Tanezumab 5 Mg Treatment Arm Met Two Of Three Co-Primary Efficacy Endpoints


Friday, 19 Apr 2019 

April 18 (Reuters) - Pfizer Inc ::PFIZER AND LILLY ANNOUNCE TOP-LINE RESULTS FROM LONG-TERM PHASE 3 STUDY OF TANEZUMAB IN PATIENTS WITH OSTEOARTHRITIS.PFIZER INC - TANEZUMAB 5 MG TREATMENT ARM MET TWO OF THREE CO-PRIMARY EFFICACY ENDPOINTS.PFIZER - PATIENTS WHO GOT TANEZUMAB 2.5 MG DID NOT EXPERIENCE STATISTICALLY SIGNIFICANT IMPROVEMENT IN PAIN, PHYSICAL FUNCTION.PFIZER INC - THERE WERE 10 DEATHS IN STUDY.PFIZER - PATIENTS ON TANEZUMAB 2.5 MG DID NOT EXPERIENCE STATISTICALLY SIGNIFICANT IMPROVEMENT IN PATIENTS' OVERALL ASSESSMENT OF OA AT 16 WEEKS VERSUS NSAIDS.PFIZER INC - DISCONTINUATIONS DUE TO ADVERSE EVENTS WERE HIGHER AMONG THOSE RECEIVING TANEZUMAB COMPARED TO NSAIDS DURING 56-WEEK TREATMENT PERIOD.PFIZER INC - NINE DEATHS IN STUDY OCCURRED IN TANEZUMAB TREATMENT ARMS AND ONE DEATH IN NSAID TREATMENT ARM.PFIZER INC - NONE OF THE DEATHS IN THE STUDY WERE CONSIDERED TREATMENT-RELATED.